Clinical Trials
2
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
2
100.0%
No approval data available
- LIfT BioSciences appointed Dr. Bo Rode Hansen as interim CEO to lead the company's transition into clinical-stage development of its neutrophil-based immunotherapy platform. - The company is preparing to initiate a first-in-human Phase 1 clinical trial of its IMAN-based therapy targeting treatment-resistant cervical and head and neck cancers in early 2027. - LIfT's proprietary allogeneic Immuno-Modulatory Alpha Neutrophils represent the world's only long-lived, off-the-shelf neutrophil-based immunotherapy with demonstrated tumor-penetrating capabilities. - The therapy offers a dual mechanism approach combining direct cytotoxicity and immunomodulatory effects to overcome cancer resistance mechanisms in solid tumors.
- The 2024 Nobel Prize in Physiology or Medicine recognized the discovery of microRNAs, small RNA molecules regulating gene activity, sparking renewed interest in their therapeutic potential. - Early clinical trials of microRNA-based therapies faced setbacks due to immune responses and delivery challenges, but advancements in RNA packaging and modification are paving the way for safer and more effective treatments. - Several companies are developing microRNA therapies for conditions like epilepsy, obesity, cancer, and heart failure, with Novo Nordisk's acquisition of Cardior Pharmaceuticals signaling growing confidence in the field. - Despite past disappointments, experts believe microRNA therapeutics are nearing a tipping point, driven by the success of other RNA-based drugs and a deeper understanding of microRNA biology.
